At Your Defense: Are Physicians Actually Making More Mistakes?

At Your Defense: Are Physicians Actually Making More Mistakes?

http://journals.lww.com/em-news/Fulltext/2017/08000/At_Your_Defense__Are_Physicians_Actually_Making.11.aspx

Fatal medical errors are on the rise, alarmingly so when comparing the latest data with the watershed estimate from the Institute of Medicine that has been used for nearly two decades.

But a 2016 study by Martin Makary, MD, MPH, put the mean rate of deaths from medical error at more than double the IOM’s figure. Dr. Makary estimated that more than 250,000 deaths are now caused by medical error annually. (BMJ 2016;353:i2139.) This number is significantly higher than the IOM’s estimate of 44,000 to 98,000 in its report, “To Err is Human: Building a Safer Health System.” (Washington: National Academies Press; 2000.) But does this mean that physicians have actually made more fatal errors?

This “rise” in medical error may have less to do with an increase in incidence and more to do with growing recognition. Dr. Makary’s analysis estimated medical error to be the third most common cause of death, after only heart disease (614,348) and cancer (591,699) based on the CDC’s number of deaths in 2013. (http://bit.ly/2sHsAd1.) The CDC does not traditionally recognize medical error as a cause of death, but it would likely be underreported if it did. Nevertheless, recognizing that medical error is a substantial cause of mortality brings to light another question: Has medicine done anything to help physicians reduce it?

Back to Top | Article Outline

The Anatomy of Error

Claims of medical negligence are traditionally based on clinician error, which can be broken down into three categories. Claims can be based on allegations of diagnostic error, in which the wrong diagnosis was made or a delay in diagnosis led to patient injury. Treatment errors include medication errors like selecting the wrong intervention or treatment, delay in treatment, or the failure to perform an operation or a procedure successfully. Then there are preventive errors, which result from failure to provide prophylactic treatment, sufficient monitoring, or timely follow-up care.

A malpractice claim is founded on the allegation that a clinician failed to meet the standard of care due to his error in diagnosis, treatment, or opportunity to prevent patient injury. In fact, the story painted by a plaintiff attorney tends to portray an isolated image of a physician generating too narrow of a differential diagnosis or failing to address an abnormal lab value or stabilize an abnormal vital sign promptly. A defense attorney would never point out the three traumas, two septic patients, and one in-house code that the defendant physician also treated because this would garner no sympathy for the defendant.

The other type of error outlined in the 1999 IOM report, system error, was identified as the bigger problem in health care. System error contributes to wrong medication dosing when medicines are available in very high concentrations, wrong diagnostic testing when electronic health record screens display test selections too closely together, and delay in treating emergency medical conditions when specialists are not available.

EHRs are a common source of system error, such as when they prevent physicians from efficiently sharing relevant clinical information, creating unreadable documents and drowning us in a sea of useless data. (Table.)

Back to Top | Article Outline

Causes of Diagnostic Errors

Identifying diagnostic error is only part of the picture when trying to understand malpractice claims. Identifying the primary and contributing factors to diagnostic error brings us closer to understanding how we can prevent them. A 2007 study by Kachalia, et al., revealed that 79 (65%) of the 122 closed malpractice claims were due to missed or delayed ED diagnosis. (Ann Emerg Med 2007;49[2]:196.) The causes of these diagnostic errors were multifactorial, but the most common contributing factors included failure to order appropriate diagnostic tests, inadequate medical history or physical examination, and incorrect interpretation of diagnostic and laboratory tests, such as x-ray (62%), CT (7%), or ECG (10%).

The Kachalia study analyzed the causes of diagnostic errors, and attributed cognitive processes as the most significant contributory factor (96%). A more recent study by the Doctor’s Company cited inadequate patient assessment (52%) as the most common cause of diagnostic error. (http://bit.ly/2sHATFV.) Both studies, however, seem to underestimate the impact of ineffective workflows, cumbersome EHRs, and crowded EDs on cognitive processes. Any practicing EP would agree that our cognitive processes deteriorate at the 11th hour of a shift, after the 25th patient seen, and when we are overwhelmed by frenetic disruptions.

A Two-Pronged Approach

It is clear that we have failed to reach the IOM’s stated goal of achieving a 50 percent reduction in medical error by 2004. If the current estimates are true, we have experienced a fivefold increase in medical error. Clinical decision support has not been the panacea that was hoped for.

What we should hope for in the near future are EHRs with intuitive, user-centered design that bring only the most important clinical information to the clinician, interoperability that allows for seamless information exchange between outpatient and inpatient clinicians, and intelligent clinician decision support that avoids the mindless, irrelevant window pop-ups and alerts us only when we really need alerting.

We physicians can reduce errors in our daily practice by collaborating with our hospital administrators to create the most efficient clinical workflows, establishing evidence-based protocols that still allow for sound clinical judgment and implementing a robust risk management program in emergency medicine.

Share this article on Twitter and Facebook.

Access the links in EMN by reading this on our website or in our free iPad app, both available at www.EM-News.com.

Comments? Write to us at emn@lww.com.

Police: Pharmacist refuses to fill prescription unless woman removes clothes

Police: Pharmacist refuses to fill prescription unless woman removes clothes

http://wivb.com/2017/08/01/police-pharmacist-refuses-to-fill-prescription-unless-woman-removes-clothes/

NIAGARA FALLS, N.Y. (WIVB) — Niagara Falls police say a pharmacist coerced a woman into removing her clothes before filling her prescription Tuesday morning.

Robert Kenzia, 81, is a licensed pharmacist at McLeod’s Pharmacy in Niagara Falls.

Police charged him with Coercion after they say he refused to fill a woman’s prescription unless she removed clothing in front of him.

In addition to that, police say Kenzia threatened the woman, saying he would tell other pharmacies not to fill her prescription if his demands were not met.

The Drug Enforcement Administration (DEA) is investigating to see if any illegal activity occurred at the pharmacy.

Police say they suspect there may be other victims. If anyone has information that would benefit their investigation, police can be reached at (716) 286-4591.

Chronic Widespread Pain Patients More Likely to Die Early

Chronic Widespread Pain Patients More Likely to Die Early

Lifestyle may explain excess mortality in fibromyalgia and other chronic pain patients

https://www.medpagetoday.com/Rheumatology/Fibromyalgia/66955?xid=nl_mpt_Weekly_Education_2017-08-02&eun=g5705800d1r

People who have chronic widespread pain die earlier than those without chronic pain, reported new research from the United Kingdom, and lifestyle may play a significant role in their mortality.

Chronic widespread pain patients who participated in UK Biobank — a cohort of 500,000 people ages 40 to 69 recruited throughout Great Britain — had a mortality risk ratio (MRR) of 2.43 (95% CI 2.17-2.72), according to Gary J. Macfarlane, MD, PhD, of the University of Aberdeen, and colleagues. This excess risk was substantially reduced after adjusting for low levels of physical activity, high body mass index (BMI), poor quality diet, and smoking.

“The evidence is now clear that persons with chronic widespread pain experience excess mortality,” the researchers wrote in Annals of the Rheumatic Diseases. “UK Biobank results considerably reduce uncertainty around the magnitude of excess risk, and demonstrate that the risk is unlikely to be due to the experience of pain per se, but is substantially explained by lifestyle factors associated with having pain (poor diet, low levels of physical activity, smoking, higher BMI).”

It’s the largest study to examine the relationship between chronic widespread pain and mortality, the authors indicated, and has considerably more detailed information about potential mediators of any excess risk associated with widespread pain and death.

UK Biobank included 7,130 participants who reported “pain all over the body” for more than 3 months, and 281,718 people who did not have chronic pain. These two sub-cohorts represented the study population for the current analysis. Both groups had the same median age (58 years), but the chronic pain group was less likely to be male (36.3% versus 50%) and more likely to be heavier than normal weight (80.4% versus 63.5%). They also were twice as likely to be a current smoker (18.6% versus 9.3%) and were less physically active. Participants in UK Biobank were recruited throughout Great Britain from 2006 to 2010; information about deaths in this group was available through mid-2015.

The researchers found that, after adjusting for age and sex and excluding deaths that occurred in the first two years, participants with chronic widespread pain had a more than twofold risk of dying in the follow-up period. Adjusting for age and sex, they found that excess risk of death stemmed from cancer (MRR 1.73; 95% CI 1.46-2.05), cardiovascular disease (MRR 3.24; 95% CI 2.55-4.11), respiratory disease (MRR 5.66; 95% CI 4.00-8.03), and other disease-related causes (MRR 4.04; 95% CI 3.05-5.34).

They also examined to what extent factors associated with pain also predicted death. They found that age- and gender-adjusted risk of death was higher for participants in the two highest BMI categories than for people of normal weight: those who were 35-39 kg/m2 had an MRR of 5.54 (95% CI 5.08-6.03), and those 40kg/m2 or greater had an MRR of 9.02 (95% CI 8.23-9.89). They also observed that participants who reported no walking, versus those walking 1-100 minutes per week, had an MRR of 4.15 (95% CI 3.77-4.57). People who reported no moderate physical activity, versus those who reported 1-60 minutes of moderate physical activity per week, had an MRR of 2.95 (95% CI 2.74-3.19). Risk of death also was higher in current smokers, who had an MRR of 2.54 (95% CI 2.39-2.70) versus non-smokers.

When they adjusted the risk models to see how lifestyle variables like BMI, physical activity, smoking, and diet might attenuate the relationship between chronic widespread pain and excess mortality, they still saw an excess risk of cardiovascular and respiratory deaths, but no longer an excess risk of cancer death.

Lifestyle factors are important intervention targets for patients with chronic widespread pain, the authors concluded. They observed that optimal management of fibromyalgia should include exercise, for example, but that is not often provided in a structured way to help patients make long-term behavioral changes.

“Few patients with chronic widespread pain or fibromyalgia receive specific supported care in improving diet or stopping smoking,” they wrote. “The data from this study show that changing the habits of persons with chronic widespread pain to be similar to persons without chronic widespread pain could reduce mortality by around 35%.”

The researchers also incorporated their results into a meta-analysis with five other published reports to evaluate evidence linking pain and mortality. Studies included in the meta-analysis were observational, used a population sampling frame, identified widespread pain or chronic widespread pain (including fibromyalgia), and quantified the relationship between chronic widespread pain and death.

“The meta-analysis of this relationship shows that all 6 studies find excess mortality and estimate the excess risk across all studies at 59%, although there is significant heterogeneity,” the authors wrote. “Similar excesses of cancer and cardiovascular mortality are observed.”

“In UK Biobank, adjustment for lifestyle factors substantially reduced the excess risk, and this observation is consistent with them mediating the relationship between chronic widespread pain and mortality,” they added.

Wisdom from Ken McKim

Purdue Pharma has to help pay for treatment of abuse of ILLEGAL SUBSTANCES ?

Pharma company settles lawsuit in Canada preventing further action on opioid crisis

www.rumblenews.net/pharma-companies-lawsuits-opioid-crisis/

Pharmaceutical company Purdue, which produces the prescription drug OxyContin that is causing widespread overdoses in Canada and the US, are on the verge of a settlement with provincial governments which could bar any further action from being taken against them in combating the opioid crisis.

As the Globe and Mail reported on Monday:

Purdue Pharma, maker of the prescription painkiller OxyContin, has agreed to pay $20-million, including $2-million to provincial health insurers, to settle the long-standing class-action suit. An Ontario court judge approved the proposed national settlement two weeks ago.

On Tuesday the settlement was approved by Nova Scotia, one of the last provinces that had yet to accept the terms of the agreement.

The lawsuit was the result of a class action on the part of up to 1,500 Canadians who suffered from addiction. But some are opposed to the decision as an acceptance of the funds would prevent any further legal action from being brought against the company as a condition of the settlement.

The settlement says class members and provincial health insurers are barred from “initiating, asserting or prosecuting any claim, action, litigation, investigation or other proceeding in any court of law…or any other forum.”

According to the most recent numbers from the Canadian Institute for Health Information, the settlement accounts for only a fraction of the money that is spent to combat addiction. as the Globe pointed out:

The provinces’ public drug plans spent $423.3-million over a five-year period on medications used for addiction to prescription painkillers and illicit opioids.

The National Post reported on Tuesday, a few provinces have yet to accept the settlement which does not find the drug company liable for the addictions its drugs caused.

Purdue did not admit liability in the national settlement, which still must be approved by courts in Saskatchewan and Quebec before individual payments that the judge estimated to average between $13,000 and $18,000 begin to flow.

Similar lawsuits have taken place in the United States which is dealing with a similar opioid problem fueled by the same pharmaceutical drugs.

In early July the Washington Post reported that the Justice Department had reached its first settlement in a slew of lawsuits that have been brought against several companies including Purdue.

Mallinckrodt Pharmaceuticals reached a $35 million settlement Tuesday to resolve allegations that the company failed to report signs that large quantities of its highly addictive oxycodone pills were diverted to the black market in Florida, where they helped stoke the opioid epidemic.

In 2007, Purdue and its top executives were found guilty of criminal violations in the companies branding which mislead doctors and patients on OxyContin’s addictive qualities. Then president of the company Michael Friedman, and others, pleaded guilty to the charges and were fined $34.5 million. According to a New York Times report on the suit:

To resolve criminal and civil charges related to the drug’s “misbranding,” the parent of Purdue Pharma, the company that markets OxyContin, agreed to pay some $600 million in fines and other payments, one of the largest amounts ever paid by a drug company in such a case.

The most recent numbers from a Canadian government report, which only recently began to collect data on opioid deaths, found that in 2016:

there were 2,458 apparent opioid-related deaths in Canada, although this figure may change as more updated data become available.

Even with the epidemic, sales of prescription opioids have continued to increase in Canada according to data from QuintilesIMS reported on by the Globe and Mail in March of 2017:

Retail pharmacies across Canada dispensed 19 million prescriptions for opioids in 2016, up slightly from 18.9 million in 2015…Prescriptions climbed six per cent over the past five years.

Blue Cross determines ADDICTION by the number of LEGAL RXS beneficiaries filled ?

Opioid addiction quintupled since 2010 and 10 other findings in new study

http://www.mlive.com/news/index.ssf/2017/07/opioid_addiction_rate_has_quin.html

2017 NATIONAL PHARMACY TECHNICIAN REGULATION SCORECARDS

2017 NATIONAL PHARMACY TECHNICIAN REGULATION SCORECARDS

https://emilyjerryfoundation.org/

 

The map on the hyperlink page is interactive…

Pharmacists are required more and more to rely on the support of technicians. But some states have seemingly placed very little necessity that the “technicians” who is assisting the Pharmacists to have any education or proper training.  Only FIVE states got a “A” while THREE states got a “ZERO”.  The primary function/charge of the Boards of Pharmacies is to protect the public’s health and safety.  You can judge from this map what states care about making sure that the technicians assisting Pharmacists are really qualified.  All states have limits on the number of technicians one Pharmacist can oversee… some states limits are TWO technicians per Pharmacists other states the ratio is UNLIMITED.  Kentucky is one of those with UNLIMITED and they received a “D” on this scorecard.

 

save image

Opioid Commission: Declare a State of Emergency, Mr President

Image result for Folktale the Sky Is Falling

Opioid Commission: Declare a State of Emergency, Mr President

http://www.medscape.com/viewarticle/883627#vp_1

 

The White House commission charged with advising the Trump administration on the country’s opioid epidemic is calling on President Donald J. Trump to declare a state of emergency to quickly and aggressively address this crisis.Some 142 Americans die every day from a drug overdose, said Chris Christie, chairman of the President’s Commission on Combating Drug Addiction and the Opioid Crisis, in a press briefing.

The declaration of a national emergency is “the single-most important recommendation,” Christie said.

The commission’s interim report, addressed to President Trump, said such a declaration would “empower your cabinet to take bold steps and would force Congress to focus on funding and empowering the Executive Branch even further to deal with this loss of life.”

 The report, released July 31, had been expected earlier, but Christie said it was delayed by the need to sift through some 8000 comments that were received after the commission held its first public meeting in mid-June.

The report made a number of recommendations, including some that would mandate physician education. Others would encourage and boost medication-assisted treatment (MAT) and increase availability of the overdose reversal agent naloxone.

The commission also urged an immediate change in Medicaid policy — one that would essentially require the federal government to pay for more addiction treatment, at a time when Congress has been looking at paring back Medicaid.

The healthcare community will play an increasingly crucial role in addressing the opioid epidemic, commission member Bertha Madras, PhD, told reporters.

“We are going to need an evolution or even a revolution in how the health care system addresses substance use issues,” said Dr Madras,  professor of psychobiology at Harvard Medical School, Boston, Massachusetts.

“Revolutionary” Approach Needed

Physicians need much more training in identifying people with substance use issues and to learn how to manage those individuals, she said. The healthcare system also frequently overlooks the fact that mental health problems are what she called a “massive contributor” to substance use disorders.

“If there isn’t an integration of mental and physical health in a revolutionary new way, we aren’t going to be able to address the entirety of the problem in a systematic and coordinated fashion,” Dr Madras said.

 The report’s recommendations call for mandatory training for those who prescribe opioids, which includes understanding risk factors for substance use disorders. This, the commission says, could be accomplished by amending the Controlled Substances Act to require all Drug Enforcement Administration (DEA) registrants to take a course in “the proper treatment of pain.”
 
The report urged adoption of the American Society of Addiction Medicine’s (ASAM) suggestion that all clinicians who apply for DEA registration to prescribe controlled substances be required to demonstrate competency in safe prescribing, pain management, and substance use identification.
 
Christie said the commissioners agree with the ASAM proposal and that it should also be applied to clinicians who seek renewal of their DEA registration.
 
The American Medical Association has repeatedly said that prescriber education should be voluntary, not mandatory.

The President’s commission is also recommending that states allow naloxone dispensing via standing orders and that clinicians be required to prescribe the overdose antidote along with high-risk opioid prescriptions.

 The commission further recommends the US Department of Health and Human Services (HHS) Secretary be granted the ability to negotiate reduced pricing on naloxone so that the drug is available to all governmental agencies and law enforcement.
 In addition, it directed HHS and other federal agencies to find a way to identify individuals who have overdosed and been revived with naloxone, so that their primary care or other healthcare providers can be identified.
 

Mandatory Use of PDMPs

Christie said the Commission also believes clinicians should be required to check a state’s prescription drug monitoring database before prescribing an opioid.

 Currently, 49 states have prescription drug monitoring programs (PDMPs). But the information in those databases is of no use if doctors aren’t required to use them, Christie said.
 The commission also recognizes that databases are not as useful as they could be because currently states share information. The report urges the president to direct Veterans Affairs and HHS to lead an effort to have all state and federal PDMPs share information by July 1, 2018.
 Information should also be shared among clinicians and families, the commission said. It recommended that patient privacy laws be amended to ensure that a patient’s substance use history can be shared by clinicians with other healthcare providers and family members. 
 “Sharing this information is appropriate in light of the crisis we are suffering,” Christie said.
 One of the Commission’s top recommendations was to rapidly expand treatment capacity, by allowing states to immediately seek waivers from a regulation that prohibits Medicaid reimbursement for services provided in inpatient facilities that have more than 16 beds.
 “This is the single fastest way to increase treatment availability across the nation,” the report said.
 The report also urges the Trump administration to find a way to create a federal incentive to boost access to MAT. All FDA-approved modes of MAT should be offered at every licensed MAT facility, and the decision should be based on what’s best for the individual, “not on what is best for the provider,” the report notes.
 The commission called for the federal government to find a way to reduce reimbursement hurdles for MAT.
 The commission’s other recommendations include:
 * That President Trump direct the Department of Labor to aggressively enforce the Mental Health Parity and Addiction Equity Act. Penalties should be levied on violators.
 * That more funding and manpower be provided to Customs and Border Protection, the Federal Bureau of Investigation, and the DEA to quickly develop ways to detect fentanyl, and that legislation be supported to stop opioids from being trafficked through the United States mail.
 The five-member commission was established by executive order and signed by President Trump on March 29. The panel is due to issue a final report in October.
 That report will focus on creating addiction prevention strategies and will take a close look at patients’ “satisfaction with pain” measure, which the federal government currently uses as a means of evaluating physicians.
 
“We believe this may very well have proven to be a driver for the incredible amount of prescribing of opioids,” said Christie.
 
He noted that in 2015 enough opioids were prescribed so that every American could be medicated for three weeks. “It’s an outrage,” said Christie.

gives the Attorney General of the United States unchecked authority to outlaw any substance

Image result for graphic state of emergency Escalating The War On Drugs – The SITSA Act is Approved in Committee

www.nationalpainreport.com/escalating-the-war-on-drugs-the-sitsa-act-is-approved-in-committee-8834122.html

This month, the House Judiciary Committee quietly approved a bill that would amend the Controlled Substance Act and give the Attorney General of the United States unchecked authority to outlaw any substance that meets a broad set of new criteria. As the opioid crisis in the United States rages on, lawmakers and the Trump Administration are eager to pass new legislation they believe will combat the epidemic and reduce the number of Americans that die each year due to an opioid overdose (In 2015, the CDC estimates 33,000 deaths were attributed to opioid overdoses).

The Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 (SITSA) would create a new scheduling category under the Controlled Substances Act, known as schedule A, for substances that “resemble currently scheduled substances” and have an “actual or predicted stimulant, depressant, or hallucinogenic effect on the central nervous system similar or greater to that of currently scheduled substances.” Under this new schedule, the DEA and the Attorney General will have the authority to circumvent existing procedures required to schedule any new substance.

Under current drug laws, the DEA must provide real and objective evidence to justify the scheduling of a substance. They must consult with Health and Human Services and complete an 8-factor analysis of the substance that evaluates the potential for abuse and the risk to public safety amongst other things. The DEA has complained this is an “arduous and time-consuming process” that hamstrings their ability to crack down on newly created synthetic substances.

Critics of the bill are concerned about the broad powers that would be granted to the Attorney General to escalate the war on drugs and infringe on civil liberties.

 

Many in the kratom community believe that the passage of this legislation would eventually result in the scheduling of kratom, an unregulated plant from Southeast Asia that is considered by many to be one of the best tools known to ease opiate withdrawal symptoms. The DEA attempted to make kratom a schedule 1 substance in September of last year only to withdraw their plans after huge public backlash of the decision. The independent 8 factor analysis that the DEA had to request from Health and Human Services concluded that kratom should not be scheduled. If the SITSA Act is signed into law, Attorney Jeff Sessions would have the power to outlaw substances like kratom without consulting with Health and Human Services and without performing the due diligence that is required of the DEA today, effectively expanding the power of the federal government and reducing its accountability to science and the public’s wishes.

About Author

Andrew is a libertarian and the owner of The Kratom Connection.

Sources

https://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/UCM180870.pdf

https://judiciary.house.gov/wp-content/uploads/2017/06/DEA-Ashley-Synthetics-Testimony-HJC-Crime-Subcommittee-27June2017.pdf

http://reason.com/blog/2017/07/13/house-advances-bill-that-would-broaden-t

https://www.washingtonpost.com/news/wonk/wp/2017/06/16/congress-is-considering-a-bill-that-would-expand-jeff-sessions-power-to-escalate-the-war-on-drugs/?utm_term=.d0f89255c545

Missouri’s PDMPs, doesn’t make information available to doctors and other prescribers

There’s Something Strange About Missouri’s New Opioid Law

www.motherjones.com/politics/2017/07/theres-something-strange-about-missouris-new-opioid-law/

It’s the only state where doctors can’t see which patients are “shopping around” for opioid prescriptions.

Calling opioid addiction a “modern plague,” Missouri Governor Eric Greitens signed an executive order on Monday establishing a statewide prescription drug monitoring program, ending Missouri’s holdout as the only state without such a program. 

But Missouri’s latest legislation is very different from other PDMPs, because it doesn’t make information available to doctors and other prescribers. In every other state, the programs provide databases that allow healthcare practitioners to make sure that patients aren’t “doctor-shopping,” or getting opioid prescriptions from multiple providers. 

The databases have a mixed reputation, in part because their use is limited: One study found that only about half of primary care doctors use the programs; another found that that only a third of prescribers are registered in the systems. Critics also say that the databases alone won’t solve the problem, particularly as drug users often transition from prescription pills to illicit drugs like heroin and fentanyl. Still, the Centers for Disease Control and Prevention calls PDMPs “among the most promising state-level interventions to improve painkiller prescribing” and advocates for states to adopt mandatory prescriber participation.

Missouri has long been the single state without such a program, despite repeated attempts to pass legislation authorizing a PDMP. That’s because of a small but vocal group of state legislators, led by State Senator Rob Schaaf, who argue that making such databases available to prescribers violates patient privacy. (Schaaf also once said of drug users, “If they overdose and kill themselves, it just removes them from the gene pool,” after filibustering a 2012 version of the bill.) In the meantime, counties covering more than half the state’s population have implemented their own monitoring programs.  

After efforts to implement a monitoring program repeatedly died in the legislature, Greitens took another tack. The executive order authorizes the state to contract with private pharmacy benefit management organizations, which amass and analyze data from insurers on which doctors are prescribing what medications. The organizations will provide data on the healthcare practitioners who stand out for over-prescribing opioids to the state’s Department of Health and Senior Services (DHSS), which will in turn refer cases to law enforcement and state licensing boards. The state has already entered a $250,000 contract with Express Scripts, a benefits manager, says state DHSS director Dr. Randall Williams. Talks with other such managers, like CVS and UnitedHealth, are in the works, he added.

“When we identify those doctors through the data analytics, we can either turn them over to law enforcement if we think it’s egregious—they’re selling or prescribing drugs for profit,” said Williams. “Or we can turn them over to the Missouri healing arts board for remediation or suspension or revocation.”

The announcement immediately drew criticism from public health advocates who contend that a PDMP will not succeed without doctors on board and addiction treatment targeted at those patients abusing prescription drugs. 

“While I certainly welcome the Governor’s attention to this crisis, I have serious questions about how meaningful this action will be if doctors writing prescriptions—and pharmacists filling those prescriptions—don’t have access to this database,” said Sen. Claire McCaskill (D-Mo.) in a statement. “The welcome mat is still out for drug dealers to shop for prescriptions in our state.”

“A PDMP that providers can’t access is much less likely to be effective because you lose all the eyes and ears on the front line (e.g., doctors) and instead just have your central team looking for anomalies in a database,” wrote Keith Humphreys, a Stanford University psychiatry professor who advised the Obama administration on drug policy, in an email.

The contract with Express Scripts—and Greitens’ announcement of the executive order at the Express Scripts office—also raised some eyebrows, as the company supported Greitens’ inauguration festivities. Asked if the decision to contract with Express Scripts was influenced by the company’s financial support, Williams said, “Absolutely not.” After so many failed attempts to pass PDMP legislation, he said, the governor was looking for an alternative way to track prescription data.